Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 343,912 |
|
|||||
| News | - | ||||||
| Day High | 3.02 | Low High |
|||||
| Day Low | 2.75 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rezolute Inc | RZLT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.11 | -3.85% | 2.75 | 18:17:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.86 | 2.75 | 3.02 | 2.89 | 2.86 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,017 | 343,912 | $ 2.87 | $ 987,682 | - | 0.72 - 3.69 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:33:23 | 20 | $ 2.7625 | USD |
Rezolute Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 114.52M | 39.63M | - | 0 | -51.79M | -1.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rezolute News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RZLT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.42 | 3.69 | 2.67 | 3.16 | 462,869 | -0.67 | -19.59% |
| 1 Month | 2.13 | 3.69 | 2.1001 | 2.87 | 340,620 | 0.62 | 29.11% |
| 3 Months | 1.13 | 3.69 | 0.9199 | 2.03 | 338,464 | 1.62 | 143.36% |
| 6 Months | 1.01 | 3.69 | 0.72 | 1.72 | 223,549 | 1.74 | 172.28% |
| 1 Year | 1.91 | 3.69 | 0.72 | 1.70 | 129,990 | 0.84 | 43.98% |
| 3 Years | 6.77 | 17.39 | 0.72 | 3.29 | 93,456 | -4.02 | -59.38% |
| 5 Years | 20.14 | 21.20 | 0.72 | 3.39 | 82,139 | -17.39 | -86.35% |
Rezolute Description
| Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. |
